In lymphoma patients mean antibody levels and seroconversion rates were lower than in other hematologic malignancies patients, primarily because all nine patients who had received rituximab within six months before COVID-19 failed to produce anti-nucleocapsid and anti-spike-antibody.
[Blood Cancer Journal]
6445218
{6445218:AAAAAAAA}
apa
50
1
166837
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/